AMRN

Steven B. Ketchum

Known title: Chief Scientific OfficerCIK: 0001289884

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 30, 2026

Amarin (AMRN) sees competition as Teva pushes branded drugs. Teva Pharmaceutical announced that branded drugs will be a central part of its growth plan. This focus highlights the competitive environment for other companies with specialty branded products, such as Amarin’s Vascepa. The news may influence market perception of Amarin’s positioning within the branded drug space.

this person other insiders at AMRN

Transaction History

AMRN▲ Buy—
AMRN▼ Sell$30K
AMRN▲ Buy—
AMRN▼ Sell$19K
AMRN▲ Buy—
AMRN▼ Sell$16K
AMRN▲ Buy—
AMRN▼ Sell$28K
AMRN▲ Buy—
AMRN▼ Sell$12K
AMRN▲ Buy—
AMRN▼ Sell$15K
AMRN▲ Buy—
AMRN▼ Sell$13K
AMRN▲ Buy—
AMRN▼ Sell$18K
AMRN▲ Buy—
AMRN▼ Sell$9K
AMRN▲ Buy—
AMRN▼ Sell$23K
AMRN▲ Buy—
AMRN▼ Sell$28K
AMRN▲ Buy—
AMRN▼ Sell$27K
AMRN▲ Buy—
AMRN▼ Sell$7K
AMRN▲ Buy—
AMRN▼ Sell$20K
AMRN▼ Sell$27K
AMRN▲ Buy—
AMRN▼ Sell$14K
AMRN▲ Buy—
AMRN▼ Sell$16K
AMRN▲ Buy—
AMRN▼ Sell$26K
AMRN▲ Buy—
AMRN▼ Sell$25K
AMRN▲ Buy—
AMRN▼ Sell$20K
AMRN▲ Buy—
AMRN▼ Sell$11K
AMRN▲ Buy—
AMRN▼ Sell$18K
AMRN▲ Buy—
AMRN▼ Sell$17K
AMRN▲ Buy—
AMRN▼ Sell$82K
AMRN▲ Buy—
AMRN▲ Buy—
AMRN▲ Buy—
AMRN▼ Sell$17K

We use analytics to understand how market-wall is used. No personal data is sold.